These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 18652869)

  • 1. Microglial activation in schizophrenia and minocycline treatment.
    Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Oct; 32(7):1758-9; author reply 1760. PubMed ID: 18652869
    [No Abstract]   [Full Text] [Related]  

  • 2. Minocycline improves recognition memory and attenuates microglial activation in Gunn rat: a possible hyperbilirubinemia-induced animal model of schizophrenia.
    Liaury K; Miyaoka T; Tsumori T; Furuya M; Hashioka S; Wake R; Tsuchie K; Fukushima M; Limoa E; Tanra AJ; Horiguchi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Apr; 50():184-90. PubMed ID: 24389395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical potential of minocycline for schizophrenia.
    Miyaoka T
    CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):376-81. PubMed ID: 18991666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormality of cerebral perfusion in the posterior cingulate gyrus of a refractory patient with schizophrenia and minocycline treatment.
    Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1132; author reply 1133-4. PubMed ID: 20433888
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful use of add-on minocycline for treatment of persistent negative symptoms in schizophrenia.
    Jhamnani K; Shivakumar V; Kalmady S; Rao NP; Venkatasubramanian G
    J Neuropsychiatry Clin Neurosci; 2013; 25(1):E06-7. PubMed ID: 23487204
    [No Abstract]   [Full Text] [Related]  

  • 6. [Minocycline for schizophrenia: a brief overview].
    Hovens JE; Onderwater TA
    Tijdschr Psychiatr; 2014; 56(6):402-6. PubMed ID: 24953514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroinflammation in schizophrenia especially focused on the role of microglia.
    Monji A; Kato TA; Mizoguchi Y; Horikawa H; Seki Y; Kasai M; Yamauchi Y; Yamada S; Kanba S
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Apr; 42():115-21. PubMed ID: 22192886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Redox and microglia in the pathophysiology of schizophrenia].
    Kato TA; Hyodo F; Yamato M; Utsumi H; Kanba S
    Yakugaku Zasshi; 2015; 135(5):739-43. PubMed ID: 25948311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early microglial inhibition preemptively mitigates chronic pain development after experimental spinal cord injury.
    Tan AM; Zhao P; Waxman SG; Hains BC
    J Rehabil Res Dev; 2009; 46(1):123-33. PubMed ID: 19533525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reaction on 'Minocycline for schizophrenia: a brief overview'].
    Evers R; van Amelsvoort T
    Tijdschr Psychiatr; 2014; 56(8):561-2. PubMed ID: 25132598
    [No Abstract]   [Full Text] [Related]  

  • 11. Antipsychotic-minocycline-acetylcysteine combination for positive, cognitive, and negative symptoms of schizophrenia.
    Koola MM
    Asian J Psychiatr; 2019 Feb; 40():100-102. PubMed ID: 30776665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms.
    Kelly DL; Vyas G; Richardson CM; Koola M; McMahon RP; Buchanan RW; Wehring HJ
    Schizophr Res; 2011 Dec; 133(1-3):257-8. PubMed ID: 21872445
    [No Abstract]   [Full Text] [Related]  

  • 13. Can inhibition of microglial activation cure schizophrenia?
    Hashioka S; McGeer PL; Miyaoka T; Wake R; Horiguchi J
    Schizophr Res; 2015 Oct; 168(1-2):583-4. PubMed ID: 26254144
    [No Abstract]   [Full Text] [Related]  

  • 14. Biological underpinnings of treatment resistance in schizophrenia: an hypothesis.
    Bartzokis G; Altshuler L
    Psychopharmacol Bull; 2003; 37(4):5-7. PubMed ID: 15272475
    [No Abstract]   [Full Text] [Related]  

  • 15. Minocycline as adjunctive therapy for schizophrenia: an open-label study.
    Miyaoka T; Yasukawa R; Yasuda H; Hayashida M; Inagaki T; Horiguchi J
    Clin Neuropharmacol; 2008; 31(5):287-92. PubMed ID: 18836347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional neuroimaging of minocycline's effect in a patient with schizophrenia.
    Chaves C; de Marque CR; Wichert-Ana L; Maia-de-Oliveira JP; Itikawa EN; Crippa JA; Zuardi AW; Todd KG; Baker GB; Dursun SM; Hallak JE
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):550-2. PubMed ID: 20138948
    [No Abstract]   [Full Text] [Related]  

  • 17. Deep hypothermia attenuates microglial proliferation independent of neuronal death after prolonged cardiac arrest in rats.
    Drabek T; Tisherman SA; Beuke L; Stezoski J; Janesko-Feldman K; Lahoud-Rahme M; Kochanek PM
    Anesth Analg; 2009 Sep; 109(3):914-23. PubMed ID: 19690267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minocycline, a microglial inhibitor, diminishes terminal patients' delirium?
    Hayakawa K; Kato TA; Kohjiro M; Monji A; Kanba S
    Am J Geriatr Psychiatry; 2014 Mar; 22(3):314-5. PubMed ID: 24507625
    [No Abstract]   [Full Text] [Related]  

  • 19. Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms.
    Padi SS; Kulkarni SK
    Eur J Pharmacol; 2008 Dec; 601(1-3):79-87. PubMed ID: 18952075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebral inflammation contributes to encephalopathy and brain edema in acute liver failure: protective effect of minocycline.
    Jiang W; Desjardins P; Butterworth RF
    J Neurochem; 2009 Apr; 109(2):485-93. PubMed ID: 19220703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.